- Home
- SRBK vs ANTX Comparison
SRBK vs ANTX Comparison
Compare SRBK & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.64
Company Overview
Basic Information| Metric | SRBK | ANTX |
|---|---|---|
| Founded | 1887 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.1M | 170.6M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SRBK | ANTX |
|---|---|---|
| Price | $19.30 | $4.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 41.1K | ★ 319.0K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 138.36 | 32.56 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $96.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.30 | $1.00 |
| 52 Week High | $19.61 | $6.91 |
Technical Indicators
Market Signals| Indicator | SRBK | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 83.04 | 66.32 |
| Support Level | $14.41 | $1.06 |
| Resistance Level | N/A | $6.91 |
| Average True Range (ATR) | 0.48 | 0.34 |
| MACD | 0.12 | 0.11 |
| Stochastic Oscillator | 88.88 | 74.53 |
Price Performance
Historical Comparison SRBK
ANTX
About SRBK SR Bancorp Inc.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.